drugset / Trial / NCT07198217

Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient

NCT07198217 ↗

Phase 2 Recruiting 20 enrolled Zibo Municipal Hospital
NaSingle-groupOpen-labelTreatment

Summary

In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of platinum-based doublet chemotherapy followed by hypofractionated radiotherapy and Tislelizumab in patients with stage IIIB/C-IV non-squamous non-small cell lung cancer. This study aims to provide more treatment options for patients with locally advanced non-small cell lung cancer.

Timeline

Start
2021-05-25
Primary completion
2025-09-28
Completion
2027-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tislelizumab Monoclonal antibody — —